StockLogistics
2 years ago
Last earnings was 75.12 yoy sales at the rate of sales for the quarter x 4, vs 78.65 OS,
“Second Quarter 2022 Financial Results
Total revenue was $18.8 million for the quarter ended June 30, 2022, compared with $31.0 million for the second quarter of 2021, driven by lower instrument and COVID-19 testing revenue. Base product and service revenue (excluding COVID-19 testing revenue) was $17.5 million, approximately 35% lower compared with $26.9 million for the second quarter of 2021.
GAAP net loss for the quarter ended June 30, 2022, was $63.5 million, compared with a GAAP net loss of $17.1 million for the second quarter of 2021. The year-over-year increase in GAAP net loss was driven by increases in fair value of the forward sale contract related to the Series B Preferred Stock and bridge loans aggregating $25.4 million, lower revenue, lower product and service margin, and higher operating expenses. Product line exits during the quarter negatively affected product and service gross profit and net loss by $4.7 million and $8.2 million, respectively.
Non-GAAP net loss, which excludes the fair value increases noted above, stock-based compensation, depreciation and amortization expenses, and interest expense, was $25.8 million for the quarter, compared with a non-GAAP net loss of $9.3 million for the second quarter of 2021.
Cash, cash equivalents and short-term investments as of June 30, 2022, were $211.2 million, compared with $30.0 million as of March 31, 2022.”
StockLogistics
2 years ago
“8:40a ET 10/13/2022 - Benzinga
Standard BioTools Announces Ascendas Genomics Receives NMPA Approval For Use Of Standard BioTools Microfluidics Technology To Advance The Development Of Molecular Diagnostics In China
Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose â?? Unleashing tools to accelerate breakthroughs in human healthâ?¢ â?? today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company's Biomarkâ?¢ family of systems and its Junoâ?¢ system in NMPA molecular diagnostics services, enabling an important advance for microfluidics technology in the country.
Ascendas Genomics is an innovative molecular diagnostics company with experience in developing high-performing assays for disease risk screening. Recent NMPA approval obtained by Ascendas Genomics enables further development of molecular diagnostics into the clinical market in China, expanding the application of microfluidics products and services.
This announcement builds upon a longstanding strategic partnership between Standard BioTools and Ascendas Genomics, by which Ascendas Genomics has developed and commercialized molecular diagnostic systems and assays in China using microfluidics technologies included in the Standard BioToolsâ?¢ Biomark real-time PCR and Juno systems.
"Ascendas recently started to approach several large CLIA labs in China, and they love Standard BioTools' microfluidics solution because of its automation, accuracy and simplicity," said Dr. Chengyong Yang, Chairman and CEO of Ascendas Genomics, referring to labs sanctioned under the Clinical Laboratory Improvement Amendments (CLIA). "Quantitative PCR is the gold standard for disease testing. High-throughput microfluidic qPCR technology creates a value different from traditional qPCR systems and could potentially become the gold standard for multiplex molecular diagnostic testing."
"Microfluidics technology plays a significant role in accelerating genomics analysis," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We are very pleased to continue our partnership with Ascendas Genomics to further expand our market position in China and better support testing and disease risk screening. We congratulate Ascendas Genomics on its recent approval and will work together to blend the scalable efficiencies of Biomark Xâ?¢ and Juno with Ascendas Genomics' expertise to advance precision medicine in China."
Used by researchers around the world to detect somatic and genomic variations from patient samples, microfluidics technology offers highly scalable and automated workflows for quantitative PCR and enables the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of molecular testing.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.“
StockLogistics
2 years ago
“8:30a ET 10/6/2022 - Globe Newswire
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needsGlobeNewswireOctober 06, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose -â?¯Unleashing tools to accelerate breakthroughs in human health(TM) - today announced the launch of the X9(TM) Real-Time PCR System, an innovative high-capacity genomics instrument offering superior efficiency.
X9 enables high data output with more than 9,000 individual nanoliter-volume reactions in a single run, ensuring cost-effective, comprehensive sample profiling with minimal operator contribution. Instead of using 96 plates worth of reagents, plastic and labor, X9 can reduce an experiment to a single integrated fluidic circuit (IFC) - a microfluidic chip. The X9 platform, powered by single-touchpoint operation, streamlines laboratory processes by integrating reaction setup into an automated workflow that generates up to 46,080 datapoints per 8-hour shift.
Agricultural genomics and clinical research labs require the flexibility to adapt to changing assay needs, so the ability to mix and match assays for quick and easy implementation with up to 96 targets is key. The X9 System integrates proven Standard BioTools(TM) proprietary microfluidics technology, which helps reduce experimental costs while accommodating relevant and popular applications and chemistries to meet the most demanding customer needs.
"We are committed to connecting the best solution to the needs of the customer, considering cost per sample or per run, throughput requirements, time to results and flexibility of content, among other factors," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Even with ongoing challenges of labor shortages and limited resources, labs are pressed to maintain the same level of output. X9 can help solve these issues by empowering these labs to work within their resources and do more with less.
"We are thrilled that this instrument is primed to support the researchers and core labs in agricultural genomics and clinical research communities, consistent with our sharpened commercial focus on high-value niche markets for specialized applications for which our platform is ideally suited. The system can support various real-time PCR studies, offering faster data output and better use of time."“
loniee
15 years ago
Ha Ha...a 4/20 fins...Must be high...lol
.................
LaBranche & Co Inc. to Broadcast Review of First Quarter 2010 Earnings Live over the Internet
LaBranche & Co Inc. (NYSE: LAB) (the “Company”) announced today that it will release first quarter 2010 financial results before the open of the market on Tuesday, April 20, 2010. The Company will host a conference call which will be broadcast live over the Internet on Tuesday, April 20, 2010 at 9:00 a.m. Eastern Time. The broadcast will be hosted on the Company’s web site located at www.labranche.com.
Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. An online archive of the broadcast will be available within two hours of the live call.
The Company is the parent of LaBranche Structured Holdings, Inc., whose subsidiaries are market-makers in options, exchange-traded funds and futures on various exchanges domestically and internationally, and LaBranche Financial Services, LLC, which provides securities execution, fixed income and brokerage services to institutional investors.
loniee
15 years ago
LaBranche & Co Inc. Announces Final Results of Its Cash Tender Offer
LaBranche & Co Inc. (NYSE:LAB) (the “Company”) today announced the final results of its previously announced offer to purchase for cash (the “Tender Offer”) up to 15 million shares of its common stock. The Tender Offer expired on March 1, 2010, at 5:00 p.m., New York City time (the “Expiration Date”).
The depositary for the Tender Offer, BNY Mellon Shareowner Services, has advised the Company that 8,539,667 million shares of its common stock (including 282,342 shares tendered through guaranteed delivery procedures) were validly tendered and not validly withdrawn pursuant to the Tender Offer, representing approximately 16.6% of its outstanding common stock as of January 28, 2010. All shares that were validly tendered and not validly withdrawn have been accepted for purchase.
The information agent for the Tender Offer is Morrow & Co., LLC. Questions and requests for information about the Tender Offer should be directed to Morrow & Co. at (800) 607-0088.
THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL SHARES OF LABRANCHE & CO INC.’S COMMON STOCK.
The Company is the parent of LaBranche Structured Holdings, Inc., whose subsidiaries are market-makers in options, exchange-traded funds and futures on various exchanges domestically and internationally, and LaBranche Financial Services, LLC, which provides securities execution, fixed income and brokerage services to institutional investors.
Certain statements contained in this release, including without limitation, statements containing the words “believes,” “intends,” “expects,” “anticipates,” and words of similar import constitute forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance, and since such statements involve risks and uncertainties, the actual results and performance of the Company and the industry may turn out to be materially different from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company also disclaims any obligation to update its view of any such risks or uncertainties or to publicly announce the result of any revisions to the forward-looking statements made in this release. Notwithstanding anything in this release, the safe harbor protections of the Private Securities Litigation Reform Act of 1995 do not apply to statements made in connection with a tender offer.
loniee
15 years ago
Now they give something good...yep...we did.didn't see this comeing
...........................
LaBranche & Co Inc. Announces Intent to Repurchase up to 15 Million Shares of Its Common Stock at a Price of $4.60 Per Share ...
LaBranche & Co Inc. (NYSE: LAB) (the “Company”) announced that it expects to commence a tender offer later today to purchase up to 15 million shares of its common stock at a price of $4.60 per share. The tender offer is expected to begin today, January 29, 2010, and to expire at 5:00 p.m., New York City time, on March 1, 2010, unless extended. The number of shares proposed to be purchased in the tender offer represents approximately 29.1% of the Company’s currently outstanding shares. Tenders of shares must be made prior to the expiration of the tender offer and may be withdrawn
http://ih.advfn.com/p.php?pid=nmona&article=41313587&symbol=LAB
Level up your trading with our powerful tools and real-time insights all in one place.
TrendTrade2016
2 months ago
Monksdream
2 months ago
THUMBS
15 years ago
Hot Features
Premium
